Successful Immunoglobulin Treatment for Fulminant Myocarditis and Serial Analysis of Serum Thioredoxin. A Case Report.

Shioji, Kosei; Matsuura, Yasushi; Iwase, Tomoyuki; Kitaguchi, Shouji; Nakamura, Hajime; Yodoi, Junji; Hashimoto, Takeji; Kawai, Chuichi; Kishimoto, Chiharu

doi:10.1253/circj.66.977

Cited by 33 publications

(24 citation statements)

References 23 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum concentrations have been reported to be elevated to approximately 30 ng/ml in patients with congestive heart failure, more than 100 ng/ml in a patient with fulminant myocarditis and also 64±44 ng/ml in patients with coronary spastic angina in the active stage. 21,22,24 The present data on serum TRX concentrations, combined with its known properties, suggest that the serum concentration of TRX can be used as a generalized marker for oxidative stress and redox-equilibrium, although the correlation between serum TRX concentrations and the other markers for oxidative stress remains to be clarified and needs to be examined.…”

Section: Serum Trx Concentration As a Measure Of Oxidative Stressmentioning

confidence: 86%

Serum Thioredoxin and .ALPHA.-Tocopherol Concentrations in Patients With Major Risk Factors

Miwa

Kishimoto²,

Nakamura

et al. 2005

Circ J

Self Cite

View full text Add to dashboard Cite

Section: Serum Trx Concentration As a Measure Of Oxidative Stressmentioning

confidence: 86%

Serum Thioredoxin and .ALPHA.-Tocopherol Concentrations in Patients With Major Risk Factors

Miwa

Kishimoto²,

Nakamura

et al. 2005

Circ J

Self Cite

View full text Add to dashboard Cite

“…The therapy was first demonstrated to be effective for an autoimmune disorder (idiopathic thrombocytopenic purpura) 8 and since then, it has been established as effective in the treatment of Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, dermatomyositis and Kawasaki's syndrome, and in the prevention of graft-vs-host disease in recipients of allogenic bone marrow transplants. [8][9][10][11][12][13][14][15][16][17] Benefits have been reported for many other autoimmune and systemic inflammatory conditions, but controlled trials are often lacking.…”

Section: Discussionmentioning

confidence: 99%

“…11,12 In brief, anti-macrophage (anti-Mø, M3/84, 1:400, PharMingen, San Diego, CA, USA), anti-CD4 (GK1.5, 1:50, PharMingen), anti-CD8 (53-6.7, 1:50, PharMingen), and anti-I-A b (25-9-17, 1:25, PharMingen) antibodies were applied to acetonefixed cryosections. After being washed, the sections were then exposed to a second antibody (horseradish peroxidaseconjugated antibodies), and the antibody binding was visualized with diaminobenzidine.…”

Section: Immunohistochemistrymentioning

confidence: 99%

Effects of Late Administration of Immunoglobulin on Experimental Atherosclerosis in Apolipoprotein E-Deficient Mice

Okabe

Kishimoto

Shimada

et al. 2005

Circ J

Self Cite

View full text Add to dashboard Cite

“…Furthermore, Se supplementation may additionally increase TR activity. TR is a strong defender against oxidative stress and it has been reported high in acute and reduced in chronic phase of some diseases (17).…”

Section: Monthsmentioning

confidence: 99%

Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis

2003

View full text Add to dashboard Cite

Objective: Selenium (Se) in the form of selenocysteine is an essential component of the family of the detoxifying enzymes glutathione peroxidase (Gpx) and of the iodothyronine selenodeiodinases that catalyse the extrathyroidal production of tri-iodothyronine (T 3 ). Thus, Se deficiency may seriously influence the generation of free radicals, the conversion of thyroxine (T 4 ) to T 3 and the autoimmune process. Therefore, we performed a randomised, placebo-controlled prospective study to investigate the effects of Se treatment on patients with autoimmune thyroiditis (AIT). Design and methods: Sixty five patients aged 22-61 years (median age 48 years) with AIT were recruited into two groups. Group I (Gr I) ðn ¼ 34Þ was treated with selenomethionine (Seme) 200 mg, plus L-thyroxine (LT 4 ) to maintain TSH levels between 0.3-2.0 mU/l, whereas group II (Gr II) ðn ¼ 31Þ received LT 4 plus placebo over a period of 6 months. Moreover, the pharmacokinetics of Seme were studied in 10 patients and eight volunteers at baseline and 2 h, 4 h, 6 h and 24 h after oral administration of a 200 mg tablet of Seme. Finally, Se levels were measured at the end of the study in some patients of both groups and their results were correlated with thyroid hormone levels. Results: In the pharmacokinetics study, basal serum concentration of Se ð75^6 mg=lÞ was within the reference range (70 -125 mg/l), it promptly increased at 2 h, peaked at 4 h ð147^17 mg=l; P , 0:0001Þ and it was abundant in serum at 24 h. In Gr I, antibodies against thyroid peroxidase (anti-TPO) levels showed an overall decrease of 46% at 3 months (from 1875^1039 U=l to 1013^382 U=l; P , 0:0001) and of 55.5% at 6 months. In Gr II the overall decrease of anti-TPO amounted to 21% at 3 months and to 27% at 6 months (from 1758^917 U=l to 1284^410 U=l; P , 0:005). There were no significant changes of antibodies against thyroglobulin levels between the groups. At the end of this study Se levels were found to be statistically significantly increased in Gr I (n = 9/34) compared with Gr II ðn ¼ 11=31Þ ð97^8:4 vs 79^8; P , 0:01Þ but no correlation with thyroid hormone was found. Conclusions: Seme is proven to be rapidly absorbed by the gastrointestinal tract. It appears to be useful as adjunctive therapy with LT 4 in the treatment of AIT. The exact mechanism(s) is not very well determined, it might enhance the activity of detoxifying enzymes and enforce the defense against oxidative stress.

show abstract

Successful Immunoglobulin Treatment for Fulminant Myocarditis and Serial Analysis of Serum Thioredoxin. A Case Report.

Cited by 33 publications

References 23 publications

Serum Thioredoxin and .ALPHA.-Tocopherol Concentrations in Patients With Major Risk Factors

Serum Thioredoxin and .ALPHA.-Tocopherol Concentrations in Patients With Major Risk Factors

Effects of Late Administration of Immunoglobulin on Experimental Atherosclerosis in Apolipoprotein E-Deficient Mice

Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis

Contact Info

Product

Resources

About